Could an HIV-free world be possible? It just might be with the NIH HIV Vaccine Trials Network/Janssen Pharmaceutical Companies’ MOSAICO. MOSAICO is a Phase 3 efficacy study to evaluate a vaccine combining a wide variety of HIV-1 strains contributing to the global epidemic. The study is Janssen’s largest to date with clinical sites across eight countries in North America, Latin America, and Europe and a recruitment target of 3,800 participants who are men who have sex with men (MSM), gender non-binary, and transgender, ages 18-60.
Known for her preventive healthcare initiatives for HIV in the Miami-Dade area and focus on health equity and implementation, Dr. Doblecki-Lewis’ expertise is invaluable to one of the most promising prevention efforts at the University of Miami. Those in the Miami or Broward area interested in participating in this study can learn more at 305-243-5621.
Janssen expects to have initial trial results in 2023.
Learn More
